Press Releases :: IceCure Medical Ltd. (ICCM)

Skip to main content Skip to section navigation Skip to footer

Jun 09, 2022 8:00 am EDT

IceCure Medical's ProSense® Cryoablation System Submitted for Regulatory Approval in Brazil

May 18, 2022 7:00 am EDT

IceCure Medical Reports First Quarter 2022 Financial Results and Operational Highlights

May 11, 2022 2:09 pm EDT

IceCure Medical to Report Q1 2022 Results and Conduct Conference Call May 18, 2022

Apr 27, 2022 9:00 am EDT

IceCure Medical Presents ICE3 Breast Cancer Trial Interim Data, Hosts Cryoablation Symposium & Conducts Hands-On ProSense® Training Sessions at the European Conference on Interventional Oncology

Jan 31, 2022 8:00 am EST

IceCure Medical Announces Preliminary Unaudited 2021 Year-End Financial Results

Jan 05, 2022 8:00 am EST

IceCure Medical CEO Issues Letter to Shareholders

Dec 20, 2021 8:04 am EST

IceCure Medical Receives Notice of Intention to Grant a European Patent Covering Its Cryogenic Pump

Dec 13, 2021 5:09 pm EST

IceCure Medical Ltd. Closes $17 Million Underwritten Public Offering and Partial Exercise of Over-Allotment Option

Dec 09, 2021 8:30 am EST

IceCure Medical Ltd. Announces Pricing of $15 Million Underwritten Public Offering

Dec 02, 2021 4:15 pm EST

IceCure Medical's Interim Results of the ICE3 Clinical Trial for Early-Stage Breast Cancer Cryoablation featured at the 2021 Annual Meeting of the Radiological Society of North America

Select a page:

rss_feed News RSS

IceCure Medical HQ: 7 Ha’Eshel St., PO Box 3163, Caesarea, 3079504, Israel

© 2025 All Rights Reserved IceCure Medical

Branding by

Terms of Use | Privacy | Last Updated: April 9, 2023